However, the potential role of SP1 as a therapeutic target in AD was put in doubt after the observation that its sustained pharmacological inhibition, induced by a selective SP1 inhibitor (mithramycin), caused a significative memory deficit and increased the Aβ1–42 and Aβ1–40 ratio (Citron et al., 2015). Here, SP1 is linked to Alzheimer disease.